Synergy Pharmaceuticals Inc. Raises $200M Rule 144A Offering of 7.50% Convertible Senior Notes
Sichenzia Ross Friedman Ference LLP Represents Synergy Pharmaceuticals Inc. in $200M Rule 144A Offering of 7.50% Convertible Senior Notes
New York, NY – (Global Newswire, November 5, 2014) – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical developer of drugs to treat gastrointestinal disorders and diseases, in a Rule 144A offering of $200 million of 7.50% Convertible Senior notes. The notes are convertibles into shares of Synergy Pharmaceutical’s common stock at a conversion price of approximately $3.11 per share.
The SRFF team was led by Partner Jeffrey J. Fessler.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Attorney - July 17, 2017
- Partner Harvey Kesner Rings Nasdaq Opening Bell with Laidlaw & Company (UK) Ltd. and Therapix Biosciences Ltd. - June 28, 2017
- Sichenzia Ross Ference Kesner LLP Represents Rodman & Renshaw a unit of H.C Wainwright in a$7.4 Million Public Offering of Medical Transcript Billing, Corp. - June 28, 2017